FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: A diagnostic study

The Lancet Neurology

Volumn 10, Issue 9, 2011, Pages 806-818

  Suomalainen, Anu ^a,b   Elo, Jenni M ^a   Pietiläinen, Kirsi H ^a   Hakonen, Anna H ^a   Sevastianova, Ksenia ^a   Korpela, Mari ^b   Isohanni, Pirjo ^a,b   Marjavaara, Sanna K ^a   Tyni, Tiina ^a,b   Kiuru Enari, Sari ^b   Pihko, Helena ^b   Darin, Niklas ^a   Õunap, Katrin ^d   Kluijtmans, Leo A J ^e   Paetau, Anders ^b   Buzkova, Jana ^a   Bindoff, Laurence A ^a   Annunen Rasila, Johanna ^c   Uusimaa, Johanna ^c   Rissanen, Aila ^a   Yki Järvinen, Hannele ^h   Hirano, Michio ^f   Tulinius, Mar ^g   Smeitink, Jan ^e   Tyynismaa, Henna ^a   more..

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d TARTU UNIVERSITY HOSPITAL   (Estonia)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Howard Hughes Medical Institute   (United States)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FIBROBLAST GROWTH FACTOR 21; LACTIC ACID; PYRUVIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STARVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFANT; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80051667626     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70155-7     Document Type: Article

References (33)

1. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008, 83:254-260.
2. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008, 63:35-39.
3. Skladal D, Halliday J, Thorburn DR Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003, 126:1905-1912.
4. Di Donato S Multisystem manifestations of mitochondrial disorders. J Neurol 2009, 256:693-710.
5. Smeitink JA, Zeviani M, Turnbull DM, Jacobs HT Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. Cell Metab 2006, 3:9-13.
6. Finsterer J, Harbo HF, Baets J, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009, 16:1255-1264.
7. Suomalainen A Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011, 34:277-282.
8. Shaham O, Slate NG, Goldberger O, et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci USA 2010, 107:1571-1575.
9. Medja F, Allouche S, Frachon P, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. Mitochondrion 2009, 9:331-339.
10. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
11. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
12. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
13. Tyynismaa H, Carroll CJ, Raimundo N, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 2010, 19:3948-3958.
14. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
15. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009, 71:369-375.
16. Griner PF, Mayewski RJ, Mushlin AI, Greenland P Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981, 94:557-592.
17. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
18. Li H, Bao Y, Xy A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156.
19. Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010, 163:469-477.
20. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010, 40:887-892.
21. Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profiles. PLoS One 2010, 5:e15534.
22. Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 2010, 33:555-561.
23. Janssen RJ, Nijtmans LG, van den Heuvel LP, Smeitink JA Mitochondrial complex I: structure, function and pathology. J Inherit Metab Dis 2006, 29:499-515.
24. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K FGF21 is an Akt-regulated myokine. FEBS Lett 2008, 582:3805-3810.
25. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol Pharmacol 2008, 74:403-412.
26. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008, 8:169-174.
27. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008, 93:3627-3632.
28. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
29. Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010, 24:2629-2637.
30. Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011, 96:E351-E355.
31. Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005, 77:430-441.
32. Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009, 187:875-888.
33. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-381.